



RA Update: Draft Evidence Report

NOTE (October 6, 2019):

For each of our eight-month assessments, ICER transparently publishes an iterative series of reports – Draft, Revised, and Final – to encourage maximum public engagement and feedback and to ensure that our Final Reports are as accurate and comprehensive as possible. We are careful to note that our assumptions and conclusions may change between these iterations.

After publishing a Draft Evidence Report on treatments for rheumatoid arthritis on September 26, ICER’s internal reviewers identified the need to reevaluate some of the assumptions and calculations within the draft. Instead of waiting to make these adjustments until our revised Evidence Report, we felt it would be most appropriate to issue a preliminary update so that stakeholders will have more time to react to our latest thinking around how these treatments should be modeled.

The decision to update ICER’s Draft Evidence Report is not related to hēRo3, the modeling platform upon which these economic analyses are conducted.

We plan to post a new Draft Evidence Report on October 11, including a description of what adjustments were made from the September 26 draft. A full Public Comment period will follow.

We appreciate all stakeholders’ interest in our work, as well as their patience through this process.